These findings collectively suggest that increasing levels of GIP contribute to insulin resistance as well as excessive insulin secretion (hyperinsulinemia) and β-cell hyperplasia, making it a promising therapeutic target for improving insulin sensitivity and managing metabolic disorders such as type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.